- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.07. | Novartis inks $175M option deal for Sironax's blood-brain barrier tech | ||
| 09.07. | Rhythm's phase 2 obesity pill trial hits primary endpoint, sending stock up | ||
| 09.07. | Jasper halves workforce after dud drug surprise, narrows R&D focus | ||
| 09.07. | AstraZeneca's Alexion strengthens gene therapy offering with $825M AAV capsid pact | ||
| 08.07. | Biopharma layoffs for first half of the year jump 32% YOY | ||
| 08.07. | Taiho's DMD asset fails to improve functional motor test results in phase 3 trial | ||
| 08.07. | Concentra extends biotech shopping spree by collecting Cargo | ||
| 08.07. | Rallybio shifts gears, cashing out of Recursion pact to extend runway | ||
| 08.07. | ProKidney's CKD cell therapy scores win in one half of phase 2 trial, falls short on other | ||
| 08.07. | Basilea secures $39M from BARDA as part of long-term antifungal funding plan | ||
| 07.07. | Cell therapy biotech shares first clinical data for in vivo CAR-T that attracted $1B AstraZeneca acquisition | ||
| 07.07. | CSL trims R&D team, shifts focus toward external opportunities | ||
| 07.07. | Jasper warns of restructuring after dud batch of urticaria drug derails trials, sinking stock | ||
| 07.07. | Cogent's phase 3 hits primary endpoint, building case for filing to challenge Blueprint's Ayvakit | ||
| 07.07. | Apogee claims IL-13 antibody sets new eczema treatment standard in phase 2 study | ||
| 03.07. | 4DMT lays off 25% of workforce while accelerating phase 3 eye gene therapy timeline | ||
| 02.07. | 53 biotech leaders urge FDA not to restrict mifepristone access over 'fatally flawed' report | ||
| 02.07. | Biotech VC raises $200M to focus on Japan's 'untapped source' of innovation | ||
| 02.07. | Vyne prunes psoriasis trial under FDA hold, but keeps faith in BET inhibitor | ||
| 02.07. | Biokin, having landed BMS deal, posts ph. 3 cancer win for bispecific ADC | ||
| 02.07. | Why 'emboldened' activist investors are taking the fight to biotechs | ||
| 02.07. | Organon axes 'biggest potential opportunity' after flunking phase 2 trial | ||
| 01.07. | Catalio's $400M fund takes advantage of 'historic buyer's market in biotech' | ||
| 01.07. | Processa hands cancer candidate back to Opus Genetics after deciding milestone out of reach | ||
| 01.07. | Concentra acquires IGM Biosciences, continuing M&A streak with struggling biotechs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .